Researchers have made significant progress in the development of a vaccine against Shigella, a bacterium that causes severe diarrhea and is a major cause of illness in children in developing countries. This breakthrough comes from a unique opportunity: over 150 non-human primates at a research facility became infected with Shigella over a two-year period, offering scientists a rare and valuable chance to study the disease in a controlled setting. In a study published in the latest issue of Science Translational Medicine, scientists analyzed the immune responses of the infected primates. By examining how their immune systems reacted to the bacteria, the researchers identified new ways to train immune cells to effectively fight off Shigella. This research focused on specific parts of the bacteria that the immune system can recognize and attack, linking these molecular targets to particular immune responses that are effective against pathogens. One of the most important findings was the identification of specific "notches" on these bacterial molecules where the most powerful antibodies attach. These precise points of interaction between antibodies and the bacteria are crucial for designing vaccines that can effectively stimulate the immune system. Understanding these interactions allows scientists to create vaccines that are more targeted and potentially more effective. The study highlights what the researchers call "unexpected features" of the immune response to Shigella in naturally infected primates. This discovery is a key step toward the rational design of vaccines that can be tailored to effectively combat the bacteria. The insights from this research could significantly improve the development of vaccines, ultimately helping to reduce the global burden of Shigella-related disease.